Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients.
Reine KanaanCesar YaghiCarole Saade RiachyAnders SchlosserAline HamadeUffe HolmskovMyrna Medlej-HashimGrith Lykke SorensenRania JounblatPublished in: JGH open : an open access journal of gastroenterology and hepatology (2023)
This study suggests the use of MFAP4 as a potential diagnostic noninvasive biomarker for cirrhosis screening in NAFLD patients.